266 related articles for article (PubMed ID: 21650079)
1. Critical considerations into the new EMA guideline on bioequivalence.
Marzo A; Fontana E
Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
[TBL] [Abstract][Full Text] [Related]
2. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
3. The new European Medicines Agency guideline on the investigation of bioequivalence.
Morais JA; Lobato Mdo R
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
[TBL] [Abstract][Full Text] [Related]
4. Current regulatory approaches of bioequivalence testing.
Karalis V; Macheras P
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
[TBL] [Abstract][Full Text] [Related]
5. New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.
Green WL
AAPS J; 2005 Mar; 7(1):E54-8. PubMed ID: 16146330
[TBL] [Abstract][Full Text] [Related]
6. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence studies for levothyroxine.
Bolton S
AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
[TBL] [Abstract][Full Text] [Related]
8. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
10. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
11. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
12. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
14. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
Kuribayashi R; Takishita T; Mikami K
J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
[TBL] [Abstract][Full Text] [Related]
15. What makes a generic medication generic?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
[TBL] [Abstract][Full Text] [Related]
16. Open questions on bioequivalence: some problems and some solutions.
Marzo A
Pharmacol Res; 1999 Oct; 40(4):357-68. PubMed ID: 10527649
[TBL] [Abstract][Full Text] [Related]
17. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
Marzo A; Balant LP
Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
[TBL] [Abstract][Full Text] [Related]
19. Comments on the note for guidance on bioavailability and bioequivalence in the European Union.
Calvo G
Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():11. PubMed ID: 9800721
[No Abstract] [Full Text] [Related]
20. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
